March 14, 2017. Compared with other opioids, reformulated Opana ER, along with its generic counterpart, had the highest injection abuse rates following reformulation.
Read More »On Medical Treatments & Products
NCHR Testimony at FDA Meeting about Abuse-Deterrent Opioid, Roxybond
April 5, 2017. Dr. Megan Polanin testifies at the FDA, stating that there is still abuse potential for the intranasal and intravenous use of RoxyBond in the midst of the nation’s opoiod epidemic.
Read More »NCHR Testimony at FDA on Hangover Treatments
April 4, 2017. Like many public health experts and advocates, we are very concerned about treatments that are marketed and promoted for hangovers that contain either acetaminophen or aspirin.
Read More »NCHR Testimony on Labeling and Misuse of Peroxide-Based Contact Lens Products
March 17, 2017. NCHR feels that the only way to avoid misuse and accidents with peroxide-based contact lens solution is to only make these products available behind the counter.
Read More »NCHR Testimony at the FDA Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee
October 19, 2016. In this testimony, we do not recommend this as the first drug approved for nocturia symptoms, unless there is a clinically meaningful benefit and sufficient safety profile for a clearly indicated population.
Read More »